Share this story:

China New Energy Group Company/Thrive Precision Health Announces Agreement to Acquire Two Diabetes Clinics in Hawaii

Thrive Precision Health, Inc.

Thrive Focus: Personalized Medicine - Institutionalizing Diabetes Care for Better Patient Outcomes


Spokane, WA – TheNewswire - November 17, 2023 – Thrive Precision Health ("THRV") (formerly Thrive Global Biosafety and China New Energy Group Company (with subsidiary Thrive Testing and Biosafety Inc., "CNER" or "Company") (OTC:CNER) is pleased to announce it has entered into an agreement to acquire all of the assets of two diabetes clinics in Hawaii with the plan to expand to 20 clinics.


"Diabetes is a big problem among the population in Hawaii, and our focus will be to reduce the pain, struggle, and cost of the diabetes epidemic and its co-morbidities.", stated Guy Zajonc, CEO and Chairman of Thrive Precision Health." "Acquisition of Heal Diabetes, Inc. will give us the footprint to build Thrive Clinics across Hawaii. The management team is highly skilled in delivering the newest forms of diabetes treatment."


Heal Diabetes has 2 locations operating and has billed $1.2M in diabetic care service year to date in 2023 and is seeing consistent month-over-month growth. Over 350 patients have been treated in 2023 at the Honolulu HI and Waipahu HI clinics. We plan to open two more clinics in early 2024. The first one in Waipahu to accommodate a waitlist of 200 patients.    And the second new clinic in Waianae, HI, to serve over 4,500 diabetic patients through network referrals.


"The Thrive Precision Health vision to apply advanced technology to diabetes care and individualizing each patient's care is the next evolutionary step in digital health. When advanced technology focuses on a specific problem as large as diabetes, we believe patient outcomes will be better by avoiding expensive treatments like amputation, dialysis, and chronic pain," stated Charles Elliott, President of Heal Diabetes. "Our experience in delivering care on the front lines combined with Thrive's technology is something my team wants to be part of."


THRV will start with the two operational clinics and work to fund the startup of the next two clinics in Q1 2024. Based on demographics and demand, THRV expects to serve the diabetic community across Hawaii with 20 clinics. Each clinic will have a standardized footprint with digital workflows to guide patients and clinicians on optimal care procedures.


The Hawaii State Department of Health, in their Published Hawaii Diabetes Plan 2030, states, "Diabetes costs Hawai'i $1.1 billion in direct healthcare expenditures and is currently the 8th leading cause of death in the state. Nearly one in every four healthcare dollars goes toward the care of people with diabetes. On average, people with diabetes incur more than twice the medical costs of people without diabetes.


For more details on the report, click the link below:


The acquisition is an asset purchase transaction is an all-stock acquisition and will close once Thrive Precision Health Hawaii Inc. (a wholly owned subsidiary of Thrive Precision Health Inc.) completes its mandatory credentialing in Hawaii, estimated to be 90-120 days. During this hold period, THRV will advance funds to Heal Diabetes to expand their operations and add the two new locations.


Thrive Precision Health Inc., has made an application to FINRA for a name and symbol change as it appears on the OTC Markets web site (currently reported as China New Energy Group Company, OTC:CNER).  Corporately the name has been changed in the State of Delaware and legally operates as Thrive Precision Health Inc.


About Thrive Precision Health Inc.

Thrive Precision Health, Inc. ("Thrive") is building a global diabetes care powerhouse. We are starting or acquiring established healthcare clinics specializing in diabetes care and bringing in three cutting-edge technologies to make them even better. Our goal is to provide top-notch care to patients worldwide with a seamless digital experience. Imagine if your healthcare was as unique as you are. We use AI and quantum biosensors to analyze data down to the molecular level, tailoring treatments and recommendations specifically for you. This means no more one-size-fits-all solutions. Your health decisions will be based on your personal data, ensuring you receive the most effective and personalized care possible. Leveraging this groundbreaking technology and clinical services will include Wound Care, Neuropathy Care, PIR diabetes care through advanced infusion methods, and conventional and complementary treatment to improve patient outcomes. All services will be performed within a biosafety-secured facility using our biodefense technology to protect our suspectable patients and staff from bacterial and viral infections.









Important Notice Regarding Forward-Looking Statements


This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements, other than statements of present or historical fact included in this press release, regarding the Company's future financial performance, as well as the Company's strategy, future operations, revenue guidance, projected costs, prospects, plans, and objectives of management are forward-looking statements. When used in this press release, the words "could," "should," "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," the negative of such terms and other similar expressions are intended to identify forward-looking statements. However, not all forward-looking statements contain such identifying words. These forward-looking statements are based on management's current expectations and assumptions about future events. They are based on currently available information as to the outcome and timing of future events. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release. Nothing in this release is intended to be an offer of sale or purchase of any securities nor a solicitation of any offer for the sale or purchase of any securities.


China New Energy Group Company/Thrive Precision Health Contact:

Guy Zajonc


U.S. +1 (509) 230-1177